NCT00102700View on ClinicalTrials.gov

ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Pancreatic CancerAdenocarcinoma
Interventions
DRUG

ARQ 501 in combination with gemcitabine

Trial Locations (15)

10461

Jacobi Medical Center, The Bronx

15232

University of Pittsburgh Medical Center, Pittsburgh

21231

The Sidney Kimmel Comprehensive Cancer Center, Baltimore

23230

Virginia Cancer Institute, Richmond

36693

University of South Alabama, Mobile

40536

University of Kentucky Medical Center, Lexington

Unversity of Kentucky Medical Center - Markey Center, Lexington

60637

University of Chicago Medical Center, Chicago

77030

Baylor College of Medicine, Houston

92093

Moores UCSD Cancer Center, La Jolla

92121

Scripps Cancer Center, San Diego

92161

VA San Diego Healthcare System, San Diego

92270

Desert Hematology Oncology Medical Group, Inc., Rancho Mirage

02114

Massachusetts General Hospital, Boston

02115

Jeffrey Meyerhardt, Boston

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00102700 - ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | Biotech Hunter | Biotech Hunter